Nearly 2 years after their final transfusion with the IGF-IR inhibitor teprotumumab (Tepezza), 82% of patients with thyroid ...

Women taking the medication after 16 weeks better sensed lower concentrations of flavors and had notable changes in brain ...

For patients with cancer, the increased financial burden of high-deductible health plans and delayed access to pain meds ...

CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in ...

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits ...

Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some ...

A conversational artificial intelligence patient navigator was successful at re-engaging patients in colonoscopy screening, ...

The small-diameter OmniaSecure defibrillation lead demonstrated implant success and accuracy in placement location.

L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.

Previously, the EU protected against Creutzfeldt-Jakob disease transmission by banning blood donations from those who lived ...

The European Medicines Agency has given the go-ahead for Durveqtix to treat hemophilia B in adults and to Adzynma for ...

Ixchiq is the first vaccine for protection against chikungunya to be recommended for European Union countries.